Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
Takeda Pharmaceutical Co Ltd ADR TAK
News
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue — Update
Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
Former Takeda Employee Pleads Guilty to Defrauding Company
Takeda Gets CHMP Approval for Recombinant ADAMTS13
Alzheimer's vaccine licensing deal boosts AC Immune
AC Immunity Shares Soar on Exclusive License Deal with Takeda
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss — Update
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
Takeda Pharmaceutical's Third-Quarter Net Profit Dropped on Lower Margins — Update
Takeda Pharmaceutical's Third-Quarter Net Profit Dropped on Lower Margins
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
United States